The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona and ...

Belgium mRNA specialist Quantoom Biosciences and biologics manufacturing specialist Univercells inked a partnership deal with ...

Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing ...

GSK has brought its message about the risks of antimicrobial resistance (AMR) to commuters in London. | GSK has brought its ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

After a rough few months for Intercept and Advanz Pharma's Ocaliva on both sides of the Atlantic, the other shoe has dropped for the rare liver disease drug in Europe. | The General Court of the ...

| Takeda is focused on curbing dengue with innovative solutions and public-private partnerships to achieve the WHO’s goal of ...

By implementing the "KnippeRx Cares Technology Ecosystem," KnippeRx has developed a comprehensive end-to-end solution that ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...